Compare EVTC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | CMPS |
|---|---|---|
| Founded | 1988 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2013 | 2020 |
| Metric | EVTC | CMPS |
|---|---|---|
| Price | $27.82 | $15.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $35.80 | $25.38 |
| AVG Volume (30 Days) | 339.7K | ★ 2.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $453,869,000.00 | N/A |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $6.86 | N/A |
| P/E Ratio | $58.67 | ★ N/A |
| Revenue Growth | ★ 11.48 | N/A |
| 52 Week Low | $21.81 | $4.88 |
| 52 Week High | $34.77 | $15.87 |
| Indicator | EVTC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 59.14 |
| Support Level | $27.64 | $12.95 |
| Resistance Level | $30.40 | $15.87 |
| Average True Range (ATR) | 0.92 | 0.83 |
| MACD | -0.21 | 0.08 |
| Stochastic Oscillator | 12.57 | 74.09 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.